Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. It has a multi-stage portfolio of drug candidates powered by a robust research and development engine. Its KINect drug discovery platform, combined with its preclinical development capabilities, allows it to identify and advance potential product candidates that it may develop independently or in collaboration with third parties. It has two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment is engaged in the provision of laboratory services. Its drug candidates include Bosakitug (ATI-045), ATI-2138 and ATI-052. Its other investigational product candidates include Lepzacitinib (ATI-1777) and Zunsemetinib (ATI-450).
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļACRS
āļāļ·āđāļāļāļĢāļīāļĐāļąāļAclaris Therapeutics Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 07, 2015
āļāļĩāļāļĩāđāļWalker (Neal S)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ64
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļOct 07
āļāļĩāđāļāļĒāļđāđ701 Lee Road
āđāļĄāļ·āļāļWAYNE
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ19087
āđāļāļĢāļĻāļąāļāļāđ14843247933
āđāļ§āđāļāđāļāļāđhttps://www.aclaristx.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļACRS
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 07, 2015
āļāļĩāļāļĩāđāļWalker (Neal S)
Mr. James (Jim) Loerop
Chief Business Officer
Mr. Christopher P. Molineaux
Mr. Christopher P. Molineaux
Lead Independent Director
Lead Independent Director
Mr. William Douglas Humphries
Mr. William Douglas Humphries
Independent Director
Dr. Maxine Gowen, Ph.D.
Independent Director
Mr. Vincent J. Milano
Independent Director
Dr. Andrew N. (Drew) Schiff, M.D.
Dr. Andrew N. (Drew) Schiff, M.D.
Independent Director
Mr. Kevin Balthaser
Chief Financial Officer
Dr. Neal S. Walker
Non-Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Non-Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Dr. Hugh M. Davis, Ph.D.
President, Chief Operating Officer, Director
President, Chief Operating Officer, Director
Dr. Anand Mehra, M.D.
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. James (Jim) Loerop
Chief Business Officer
Mr. Christopher P. Molineaux
Mr. Christopher P. Molineaux
Lead Independent Director
Lead Independent Director
Mr. William Douglas Humphries
Mr. William Douglas Humphries
Independent Director
Dr. Maxine Gowen, Ph.D.
Independent Director
Mr. Vincent J. Milano
Independent Director
Dr. Andrew N. (Drew) Schiff, M.D.
Dr. Andrew N. (Drew) Schiff, M.D.
Independent Director
Invesco NASDAQ Future Gen 200 ETF
ProShares UltraPro Russell2000
Invesco RAFI US 1500 Small-Mid ETF
iShares Russell 2000 Value ETF
Global X Russell 2000 ETF
ProShares Hedge Replication ETF
Proshares Ultra Russell 2000
Avantis US Small Cap Equity ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Invesco NASDAQ Future Gen 200 ETF
āļŠāļąāļāļŠāđāļ§āļ0.7%
iShares Micro-Cap ETF
āļŠāļąāļāļŠāđāļ§āļ0.04%
iShares Russell 2000 ETF
āļŠāļąāļāļŠāđāļ§āļ0.01%
ProShares UltraPro Russell2000
āļŠāļąāļāļŠāđāļ§āļ0.01%
Invesco RAFI US 1500 Small-Mid ETF
āļŠāļąāļāļŠāđāļ§āļ0.01%
iShares Russell 2000 Value ETF
āļŠāļąāļāļŠāđāļ§āļ0.01%
Global X Russell 2000 ETF
āļŠāļąāļāļŠāđāļ§āļ0.01%
ProShares Hedge Replication ETF
āļŠāļąāļāļŠāđāļ§āļ0.01%
Proshares Ultra Russell 2000
āļŠāļąāļāļŠāđāļ§āļ0.01%
Avantis US Small Cap Equity ETF
āļŠāļąāļāļŠāđāļ§āļ0.01%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ